1315P Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumabS. Llop Serna, Ernest Nadal, J.C. Ruffinelli et al.|Annals of Oncology|2021Cited by 1